Dr. Lecia Sequist on Acquired Resistance to Oral EGFR Inhibitors in Advanced NSCLC

Join us when we catch up with Dr. Lecia Sequist from Massachusetts General Hospital in Boston, MA to review what is known and what we're still learning about resistance that develops after an initial response to EGFR tyrosine kinase inhibitor therapy for advanced non-small cell lung cancer.